Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Abroad (travel likely)Recruiting

Conditions

Blood Cancer · Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Andrew Hantel, MD) · Andrew_Hantel@dfci.harvard.edu · 617-582-9394
Contact: Principal Investigator (Andrew Hantel, MD)

Study leads

Andrew Hantel, MD
Principal Investigator
Dana-Farber Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

Long-Term Follow-Up of Recipient of Gene Transfer Research

Retroviridae Infections · Cancer

Abroad (travel likely)Recruiting

Houston, United States

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Duarte, United States

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Waldenstrom Macroglobulinemia (WM)

Abroad (travel likely)RecruitingPHASE1

Duarte, United States · Orange, United States